Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction

Laura Sun, Kathryn T. Maples, Kevin H. Hall, Yuan Liu, Yichun Cao, Nisha S. Joseph, Craig C Hofmeister, Jonathan L. Kaufman, Madhav Dhodapkar, Ajay K. Nooka, Sagar Lonial, R Donald Harvey

Blood (2022) 140 (Supplement 1): 7131–7132.

https://doi.org/10.1182/blood-2022-159189

Published: 2022

Journal Articles

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

Karen Sweiss, Pritesh Patel, Janet Guo, Kyeongmin Kim, Kasey Hill, Nicole Abbott, Jeremy Johnson, Donald Irby, John G. Quigley, Damiano Rondelli, R Donald Harvey, Ajay K. Nooka, Madhav Dhodapkar, Jonathan L. Kaufman, Nisha S. Joseph, Sagar Lonial, Douglas W. Sborov, Mitch A Phelps, Craig C Hofmeister

Blood (2022) 140 (Supplement 1): 5988–5990.

https://doi.org/10.1182/blood-2022-170778

Published: 2022

Journal Articles

A Phase 2 Evaluation of Daratumumab-Based Induction Therapy in Multiple Myeloma Patients with Severe Renal Insufficiency

R Donald Harvey, Joseph K Franz, Nisha S. Joseph, Jonathan L. Kaufman, Elise Hitron, Hannah Collins, Catherine Braga, Ludimila Cavalcante, Kathryn T. Maples, Craig C Hofmeister, Madhav Dhodapkar, Sagar Lonial, Ajay K. Nooka

Blood (2022) 140 (Supplement 1): 12633–12634.

https://doi.org/10.1182/blood-2022-157047

Published: 2022

Journal Articles

Assessment of Midostaurin in Combination with Idarubicin-Based Induction Treatment in Acute Myeloid Leukemia

Julia Lee, Charlotte B Wagner, Stacy Prelewicz, Heena P Kurish, Rob Walchack, Danielle Cenin, Seema Patel, Mimi Lo, Danielle Schlafer, Belinda KT Li, R Donald Harvey, Bestis Wasef, Jian Ying, Tibor Kovacsovics

Blood (2022) 140 (Supplement 1): 3242–3243.

https://doi.org/10.1182/blood-2022-170123

Published: 2022

Journal Articles

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Neeraj Gupta, PhD, Michael J Hanley, PhD, R. Donald Harvey, PharmD, Ashraf Z Badros, MD, Brea C. Lipe, MD, Vishal Kukreti, Jesus G. Berdeja, MD, Huyuan Yang, PhD, Ai-Min Hui, MD PhD, Xiaoquan Zhang, MD PhD, Karthik Venkatakrishnan, PhD, Ajai Chari, MD

Blood (2015) 126 (23): 4227.

https://doi.org/10.1182/blood.V126.23.4227.4227

Published: 2015

Journal Articles

Relationship of Carfilzomib Dosing and Duration of Therapy (DOT) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)

R. Donald Harvey, Yaozhu J. Chen, MPA, Jan Lethen, Maya Mahue

Blood (2015) 126 (23): 4235.

https://doi.org/10.1182/blood.V126.23.4235.4235

Published: 2015

Journal Articles

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment

Jeffrey Matous, MD, David S Siegel, MD PhD, Sagar Lonial, MD, R. Donald Harvey, PharmD, Claudia Kasserra, PhD, Yan Li, PhD, Min Chen, PhD, Thomas Doerr, MSc, Lars Sternas, MD, Mohamed H. Zaki, MD, Christian Jacques, MD, Jatin J. Shah, MD

Blood (2014) 124 (21): 4730.

https://doi.org/10.1182/blood.V124.21.4730.4730

Published: 2014

Journal Articles

Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

Jonathan L. Kaufman, MD, Todd Zimmerman, MD, Cara A Rosenbaum, MD, Ajay K. Nooka, MD MPH, Leonard T Heffner, MD, R. Donald Harvey, PharmD, Charise Gleason, MSN, ANP-BC, AOCNP, Colleen Lewis, MSN, ANP-BC, AOCNP, Cathy Sharp, RN, MN, OCN, Kenisha W Barron, B.S, CCRC, Sagar Lonial, MD

Blood (2014) 124 (21): 32.

https://doi.org/10.1182/blood.V124.21.32.32

Published: 2014

Journal Articles

Real-World Practice Patterns with Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma

R. Donald Harvey, PharmD, Ze Cong, PhD, Winifred Werther, PhD, Jan L. Lethen, MS, Sagar Lonial, MD

Blood (2014) 124 (21): 5765.

https://doi.org/10.1182/blood.V124.21.5765.5765

Published: 2014

Journal Articles

The Budget Impact of Orphan Drugs in the U.S.: A 2007-2013 MIDAS Sales Data Analysis

Victoria Divino, Mitch Dekoven, MHSA, Weiying Wang, MPH, Michael Kleinrock, MA, R. Donald Harvey, PharmD, Rolin L Wade, RPh, MS, Satyin Kaura, MSci, MBA

Blood (2014) 124 (21): 736.

https://doi.org/10.1182/blood.V124.21.736.736

Published: 2014

Journal Articles

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Paul G. Richardson, Rachid Baz, Michael Wang, Andrzej J. Jakubowiak, Jacob P. Laubach, R. Donald Harvey, Moshe Talpaz, Deborah Berg, Guohui Liu, Jiang Yu, Neeraj Gupta, Alessandra Di Bacco, Ai-Min Hui, Sagar Lonial

Blood (2014) 124 (7): 1038–1046.

https://doi.org/10.1182/blood-2014-01-548826

Published: 2014

Includes: Supplemental data

Journal Articles

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells

Yanyan Gu, Jonathan L. Kaufman, Leon Bernal, Claire Torre, Shannon M. Matulis, R. Donald Harvey, Jing Chen, Shi-Yong Sun, Lawrence H. Boise, Sagar Lonial

Blood (2014) 123 (21): 3269–3276.

https://doi.org/10.1182/blood-2013-08-521914

Published: 2014

Includes: Supplemental data

Journal Articles

Predictors Of Survival Outcomes In Phase I Relapsed Or Refractory Multiple Myeloma Patients

R. Donald Harvey, PharmD, Meagan S. Barbee, PharmD, Ajay K. Nooka, MD, MPH, Sungjin Kim, MS, Zhengjia Chen, PhD, Leonard T. Heffner, MD, Jonathan L. Kaufman, MD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 1958.

https://doi.org/10.1182/blood.V122.21.1958.1958

Published: 2013

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study

Jonathan L. Kaufman, MD, Jatin J. Shah, M.D., Jacob P. Laubach, MD, Alaina R. Mitchell, BS, Cathy Sharp, R.N., Colleen Lewis, MSN, ANP-BC, AOCNP, R. Donald Harvey, PharmD, Charise Gleason, MSN, ANP-BC, AOCNP, Daniela Casbourne, FNP-BC, AOCNP, Ajay K. Nooka, MD, MPH, FACP, Leonard T Heffner, MD, Paul G. Richardson, MD, Robert Z. Orlowski, M.D., Ph.D., Sagar Lonial, MD

Blood (2012) 120 (21): 336.

https://doi.org/10.1182/blood.V120.21.336.336

Published: 2012

Journal Articles

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

Jatin J. Shah, M.D., Jeffrey A. Zonder, MD, Adam Cohen, MD, William Bensinger, MD, Jonathan L. Kaufman, MD, Robert Z. Orlowski, M.D., Ph.D., R. Donald Harvey, PharmD, Muneer H. Abidi, MD, Sheeba K. Thomas, MD, Duncan Walker, PhD, Brandi Hilder, Ann Marie Ptaszynski, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 449.

https://doi.org/10.1182/blood.V120.21.449.449

Published: 2012

Journal Articles

A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD

Divya Tiwari, MD, John Horan, Amelia Langston, MD, Muna Qayed, M.D., M.Sc., Jennifer Carr, Heather Renfroe, Couture Cynthia, Hanna J. Khoury, MD, Robertson Jennifer, R. Donald Harvey, PharmD, Aneesh Mehta, Edmund K. Waller, MD, PhD, Leslie S. Kean, MD, PhD

Blood (2012) 120 (21): 741.

https://doi.org/10.1182/blood.V120.21.741.741

Published: 2012

Journal Articles

A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials,

Ajay K. Nooka, MD, MPH, FACP, Samatha Muppidi, MD, R. Donald Harvey, PharmD, Jonathan L. Kaufman, MD, Amelia Langston, MD, Colleen Lewis, MSN, Lawrence H. Boise, PhD, Christopher R Flowers, MD, Sagar Lonial, MD

Blood (2011) 118 (21): 3954.

https://doi.org/10.1182/blood.V118.21.3954.3954

Published: 2011

Journal Articles

Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis

R. Donald Harvey, PharmD, Susanna Joan Jacobus, MSc, S. Vincent Rajkumar, MD, Philip R. Greipp, MD, Sagar Lonial, MD

Blood (2011) 118 (21): 1882.

https://doi.org/10.1182/blood.V118.21.1882.1882

Published: 2011

Journal Articles

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Sagar Lonial, MD, Adam Cohen, Jeffrey Zonder, MD, William I Benzinger, MD, Jonathan L. Kaufman, MD, Robert Z. Orlowski, MD, PhD, R. Donald Harvey, PharmD, Raymond Alexanian, M.D., Sheeba K Thomas, M.D., Donna Weber, MD, Duncan Walker, PhD, Brandi Hilder, PhD, Ann Ptaszynski, Jatin J Shah, MD

Blood (2011) 118 (21): 2935.

https://doi.org/10.1182/blood.V118.21.2935.2935

Published: 2011

Journal Articles

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

Jatin J Shah, MD, Jeffrey Zonder, MD, Adam Cohen, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, M.D., Sheeba K Thomas, M.D., Donna Weber, MD, Jonathan L. Kaufman, MD, R. Donald Harvey, PharmD, Duncan Walker, PhD, Kevin Litwiler, PhD, Sharon Karan, Brandi Hilder, Ann Marie Ptaszynski, MD, Sagar Lonial, MD

Blood (2011) 118 (21): 1860.

https://doi.org/10.1182/blood.V118.21.1860.1860

Published: 2011

NARROW

African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

A Phase 2 Evaluation of Daratumumab-Based Induction Therapy in Multiple Myeloma Patients with Severe Renal Insufficiency

Assessment of Midostaurin in Combination with Idarubicin-Based Induction Treatment in Acute Myeloid Leukemia

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Relationship of Carfilzomib Dosing and Duration of Therapy (DOT) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment

Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

Real-World Practice Patterns with Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma

The Budget Impact of Orphan Drugs in the U.S.: A 2007-2013 MIDAS Sales Data Analysis

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells

Predictors Of Survival Outcomes In Phase I Relapsed Or Refractory Multiple Myeloma Patients

Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD

A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials,

Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only